BC Innovations | Feb 1, 2019
Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
BC Innovations | Mar 10, 2016
Tools & Techniques

Ziopharm bets on the HLA-A odds

Ziopharm Oncology Inc. is adding gene editing to its repertoire with a strategy to increase the odds of finding a match for hematopoietic stem cell transplants. While the system is still short of an allogeneic...
BC Innovations | Oct 31, 2013
Targets & Mechanisms

Personal factors

A multi-institute team collaborating with the FDA has determined why patients with a form of severe hemophilia rarely develop neutralizing antibodies against factor VIII replacement therapies. The team is also developing an algorithm to predict...
BC Innovations | Jun 7, 2012
Tools & Techniques

HLA in sequence

A group of Australian researchers and an FDA -led team have independently identified a mechanism behind human leukocyte antigen allele-mediated autoimmune reactions to certain drugs. 1,2 The findings could expand the use of human leukocyte...
BC Innovations | Oct 29, 2009
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease; Crohn's disease; multiple sclerosis (MS); myasthenia gravis; rheumatoid arthritis (RA); selective IgA deficiency; systemic lupus erythematosus (SLE); ulcerative colitis (UC) Major...
BC Innovations | Oct 22, 2009
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Markers for response to peroxisome proliferation-activated receptor-g (PPARG; PPARg) agonist therapy in insulin-resistant patients A gene expression study in human subjects identified markers that could help...
BC Innovations | Aug 7, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune Disease Multiple sclerosis (MS) Interferon-b (IFN-b); major histocompatibility complex, class II, DR-b1 (HLA-DRB1) A genetic analysis of subjects with MS...
BioCentury | Nov 17, 1997
Tools & Techniques

Other RA players speak up

Compounds targeting tumor necrosis factor alpha (TNF-a), specifically Immunex Corp. 's Enbrel and Centocor Inc. 's Avakine , are leading the pack as the potential new gold standard for rheumatoid arthritis treatment ( see BioCentury, Nov. 10...
Items per page:
1 - 8 of 8